Instem Acquires Leadscope to Integrate Key Application Areas and Accelerate Drug Development

VCBeat (WeChat: vcbeat) learned from foreign media that on November 15, 2019, local time, Instem, a global provider of IT solutions for the life sciences market, announced its acquisition of Leadscope.

Instem stated that the acquisition aims to further integrate and align key application areas, helping customers streamline and accelerate their research and development processes. The financial terms of the acquisition were not disclosed.

Instem, founded in 1969 and headquartered in Pennsylvania, USA, is a global leader in providing information solutions for life sciences R&D. Its software applications help customers enhance productivity and optimize processes, accelerating the development of pharmaceutical and chemical products to make them safer and more effective.

Instem helps its life sciences customers more effectively collect, analyze, report, and submit high-quality regulatory data, while ensuring the compliance of their products worldwide. Currently, Instem has offices in the United States, the United Kingdom, France, Japan, China, and India.

Leadscope, founded in 1997 and headquartered in Columbus, Ohio, is globally renowned for its advanced informatics, predictive technologies, and database solutions. These technologies enable organizations to effectively unlock valuable insights from both public and private research data.

Leadscope is also a renowned leader in the field of computational toxicology, serving clients that include pharmaceutical, chemical, and consumer goods organizations, as well as international regulatory agencies. Leadscope’s innovative solutions enable researchers to integrate their proprietary data with publicly curated toxicity databases. When searching Leadscope’s toxicity database, customers can access over 500,000 toxicology studies covering more than 200,000 chemical substances, thereby facilitating rapid, accurate, and defensible predictions.

Leadscope accelerates the drug development process by predicting drug toxicity through intuitive tools used by its international clients, and by providing expert review for genotoxicity, skin sensitization, carcinogenicity, acute toxicity, reproductive and developmental toxicity, organ toxicity, and environmental toxicity.

Leadscope will join Instem’s Science division, which currently provides Target Safety Assessment (TSA) services through its KnowledgeScan product. Through this acquisition, Instem will integrate a broader range of critical data to offer the market an enhanced starting point, helping customers gain clearer insights into candidate drug molecules from early-stage biology to early-stage chemistry.

Teams from Instem and Leadscope will soon exhibit and demonstrate their technical products at the 2019 Annual Meeting of the American College of Toxicology, held in Phoenix, Arizona.

Dr. Glenn Myatt, CEO of Leadscope, stated, “We are delighted to join the Instem Group, a leader in the health and life sciences sectors. The Instem brand is synonymous with innovation and market leadership; its ability to successfully balance growth while maintaining high-quality service delivery is crucial for Leadscope. As a leading provider of silico safety assessment solutions, Instem’s resources and global reach will help us better meet the growing demands of both industry and regulatory bodies.”

(Compiled by: He Li)